Arcellx (Arcellx) Additional Paid-In Capital : $874.3 Mil(As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Arcellx Additional Paid-In Capital?

Arcellx's quarterly additional paid-in capital increased from Jun. 2023 ($663.6 Mil) to Sep. 2023 ($675.5 Mil) and increased from Sep. 2023 ($675.5 Mil) to Dec. 2023 ($874.3 Mil).

Arcellx's annual additional paid-in capital increased from Dec. 2021 ($8.6 Mil) to Dec. 2022 ($523.9 Mil) and increased from Dec. 2022 ($523.9 Mil) to Dec. 2023 ($874.3 Mil).

Arcellx Additional Paid-In Capital Historical Data

The historical data trend for Arcellx's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcellx Additional Paid-In Capital Chart

Arcellx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

0.31

1.42

8.62

523.92

874.26

Arcellx Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial										523.92	649.72	663.61	675.47	874.26

Arcellx Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Arcellx Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Arcellx's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcellx (Arcellx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcellx Inc (NAS:ACLX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

25 West Watkins Mill Road, Suite A, Gaithersburg, MD, USA, 20878

Website

https://www.arcellx.com

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

Executives

Michelle Gilson	officer: Chief Financial Officer	25 WEST WATKINS MILL ROAD, SUITE A, GAITHERSBURG MD 20878
Christopher Heery	officer: Chief Medical Officer	C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Rami Elghandour	director, officer: See Remarks	15 BARCELONA CIR, REDWOOD CITY CA 94065
Jill Carroll	director	C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Sr One Capital Fund I Aggregator Lp	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Scott D Sandell	10 percent owner
Forest Baskett	10 percent owner
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Olivia C Ware	director	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Sr One Capital Management, Llc	10 percent owner	985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Sr One Co-invest Ii Manager, Llc	10 percent owner	985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Nea Partners 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093